The Oregon Alzheimer's Disease Center Biomarkers and Genetics Core was established in order to promote research utilizing genetic, plasma, and cerebrospinal fluid biomarkers of Alzheimer's disease and relevant mechanisms.
The Specific Aims are: 1) To obtain and make available for research, biomarker specimens (DNA. plasma, and CSF) from OADC subjects, including healthy control subjects, subjects with mild cognitive impairment (MCI), and subjects with AD and other demenfias. 2) To obtain and make available for research, biomarker data on OADC subjects. This will include: a) apolipoprotein E (APOE) genotype on all subjects, b) single nucleotide polymorphism (SNP) profiles on select aging cohorts, and c) CSF Ap42, tau, BDNF, and F2-isoprostanes on select cohorts, d) plasma biomarker data on select cohorts. 3) To foster collaborative research involving genetics and other biomarkers emphasizing the research focus of the OADC. Research themes supported by the Core include 1) Identification of genetic predictors of both healthy brain aging and neurodegenerative dementia;2) Identification and validation of CSF and plasma biomarkers of neurodegeneration and mechanisms of neurodegeneration suitable for identification of high risk subjects, for identification of target mechanisms, and for use as outcome measures in clinical trials;3) Identification of CSF and plasma biomarkers of environmental predictors of both healthy brain aging and neurodegenerafive dementia. The Core maintains specimen banks and provides samples to qualified investigators with appropriate IRB approvals. Clinical and other data is also made available to invesfigators within HIPAA guidelines and according to local IRB regulations.

Public Health Relevance

The increasing emphasis on early intervention to prevent Alzheimer's disease in asymptomatic subjects will require that subjects and outcomes be characterized by a variety of biomarkers rather than relying on clinical outcomes alone. The understanding and utilization of these markers of risk and surrogate markers of disease will depend on the availability of the types of samples and data to be generated by this Core.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008017-25
Application #
8662582
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
25
Fiscal Year
2014
Total Cost
$203,975
Indirect Cost
$75,462
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Teipel, Stefan; König, Alexandra; Hoey, Jesse et al. (2018) Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia. Alzheimers Dement 14:1216-1231
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Wardzala, Casia; Murchison, Charles; Loftis, Jennifer M et al. (2018) Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology (Berl) 235:761-770
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 482 publications